Sep 25th 2012 - Edison Investment Research today published a report on Evotec entitled "A €60m Contract And More To Come". In summary, the report says:
Evotec has signed a €60m contract with the National Institutes of Health (NIH) for the provision of compound management services. This deal confirms that Evotec’s acquisition of Compound Focus from Galapagos was value enhancing, further demonstrating the success of Evotec’s bolt-on acquisition strategy. Roche has started a Phase II study with EVT302 and more significant announcements are due before the end of the year. We have increased our valuation by €30m to €485m.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »